DBV Technologies S.A. (DBVT) Stock Price

DBVTStock

$14.97+58.52%52W

Market Cap$940.80M

P/E—

PEG Ratio—

Div yield—

Beta0.41

DBVT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.84%

Price vs S&P 500 (4W)2.36%

VGM Score39.36

Book Value / Share (Quarterly)$0.54

P/TBV (Annual)4.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.18%

Cash Flow / Share (Quarterly)$-0.57

Price vs S&P 500 (YTD)-35.73%

Gross Margin (TTM)93.12%

Net Profit Margin (TTM)-2611.00%

EPS (TTM)$-1.07

10-Day Avg Trading Volume1.09M

EPS Excl Extra (TTM)$-1.07

Revenue Growth (5Y)-12.95%

EPS (Annual)$-1.05

ROI (Annual)-83.94%

Gross Margin (Annual)86.43%

Net Profit Margin (5Y Avg)-1904.48%

Cash / Share (Quarterly)$0.59

Revenue Growth QoQ (YoY)115.98%

ROA (Last FY)-63.05%

Revenue Growth TTM (YoY)35.77%

EBITD / Share (TTM)$-0.97

ROE (5Y Avg)-140.82%

Operating Margin (TTM)-2606.65%

Cash Flow / Share (Annual)$-0.51

P/B Ratio5.41x

P/B Ratio (Quarterly)6.02x

Net Income / Employee (Annual)$-1,177,200

EV / Revenue (TTM)124.11x

Net Interest Coverage (TTM)-581.44x

ROA (TTM)-78.14%

EPS Incl Extra (Annual)$-1.05

Current Ratio (Annual)3.67x

Quick Ratio (Quarterly)3.54x

3-Month Avg Trading Volume0.96M

52-Week Price Return58.52%

Revenue / Employee (TTM)$45,100

Tangible BV / Share (Quarterly)$0.54

P/S Ratio (Annual)153.78x

Asset Turnover (Annual)0.02x

52-Week High$4.50

Operating Margin (5Y Avg)-1921.02%

EPS Excl Extra (Annual)$-1.05

CapEx CAGR (5Y)-27.90%

Tangible BV CAGR (5Y)-3.85%

26-Week Price Return-30.59%

Quick Ratio (Annual)3.62x

13-Week Price Return-21.67%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)3.72x

Enterprise Value$699.50M

Revenue / Share Growth (5Y)-27.98%

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)-28.16%

Revenue / Employee (Annual)$45,100

Inventory Turnover (Annual)0.55x

Pretax Margin (Annual)-2602.29%

Cash / Share (Annual)$0.82

3-Month Return Std Dev48.74%

Gross Margin (5Y Avg)88.12%

Net Income / Employee (TTM)$-1,177,200

ROE (Last FY)-87.19%

Net Interest Coverage (Annual)-52.83x

EPS Basic Excl Extra (Annual)$-1.05

Receivables Turnover (TTM)22.36x

Total Debt / Equity (Quarterly)0.05x

EPS Incl Extra (TTM)$-1.07

Receivables Turnover (Annual)5.12x

ROI (TTM)-109.34%

P/S Ratio (TTM)153.78x

Pretax Margin (5Y Avg)-1903.50%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$0.72

Price vs S&P 500 (52W)40.21%

Year-to-Date Return-25.15%

5-Day Price Return-0.55%

EPS Normalized (Annual)$-1.05

ROA (5Y Avg)-76.57%

Net Profit Margin (Annual)-2611.00%

Month-to-Date Return7.66%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-1.02

Operating Margin (Annual)-2606.65%

LT Debt / Equity (Annual)0.59x

ROI (5Y Avg)-120.91%

LT Debt / Equity (Quarterly)0.11x

EPS Basic Excl Extra (TTM)$-1.07

P/TBV (Quarterly)6.02x

P/B Ratio (Annual)4.53x

Inventory Turnover (TTM)0.83x

Pretax Margin (TTM)-2602.29%

Book Value / Share (Annual)$0.72

Price vs S&P 500 (13W)-24.47%

Beta0.41x

Revenue / Share (TTM)$0.04

ROE (TTM)-115.44%

52-Week Low$1.45

vGradeF

gGradeC

mGradeD

vgmGradeD

DBVT Earnings Surprise History

Q3 25-0.21est. -0.29

Q4 25-0.20est. -0.19

Q1 26-0.09est. -0.12

Q2 26-0.10est. -0.09

DBVT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
DBVTDBV Technologies S.A.	F	C	D	$14.97
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About DBV Technologies S.A.

DBV Technologies is a clinical-stage biopharmaceutical company developing Viaskin, a proprietary patch-based immunotherapy platform that delivers therapeutics through intact skin for immune-mediated disorders. The company's lead program, Viaskin Peanut, targets peanut allergies, with earlier-stage candidates in milk allergy and eosinophilic esophagitis. This epicutaneous delivery approach represents a differentiated mechanism to address significant unmet needs in food allergy treatment.